New Breast Cancer Drug Shows Early Trial Success
A small clinical study shows potential for a new treatment in adults with advanced HER2-positive breast cancer.
Updated on Oct. 26, 2026 in Cancer
Innovent Biologics reported a 95% response rate for its drug IBI354 in a small clinical trial for advanced HER2-positive breast cancer. The findings, presented in 2026, suggest potential for the therapy as it moves into Phase 3 testing.
Why it matters
As breast cancer research evolves, new targeted therapies are being tested to improve outcomes for patients with advanced disease. These preliminary results offer an early look at a potential treatment option, though final efficacy and safety remain to be established in larger trials.
This preliminary study evaluated 20 patients with advanced HER2-positive breast cancer who received IBI354 alongside pertuzumab. Results showed a 95% response rate and a 100% disease-control rate after a 9.6-month median follow-up.
The players
Innovent Biologics
A biopharmaceutical company focused on the development of innovative medicines for oncology and other therapeutic areas.
European Society for Medical Oncology
A global professional organization that hosts major congresses to disseminate clinical oncology research.
The details
The IBI354 therapy is administered at a dosage of 9 milligrams per kilogram of body weight every three weeks. In the study, 20% of participants experienced Grade 3 or higher treatment-related adverse events. Researchers are now transitioning the drug into Phase 3 clinical testing to further evaluate its performance compared to current standards of care.
Timeline
Results were presented at the European Society for Medical Oncology Congress in 2026.
Health Landscape
The study represents an effort to expand the toolkit of targeted therapies for advanced breast cancer, which currently relies on established monoclonal antibodies. Advancing IBI354 to Phase 3 testing reflects the ongoing push to identify durable treatment options for patients with advanced disease.
These findings are preliminary and currently limited to a small group of trial participants. Patients managing advanced breast cancer should consult with their oncology team to discuss which established therapies are appropriate for their specific diagnosis.
The takeaway
While the early 95% response rate is a notable development for this investigational drug, it is not yet a treatment available for clinical practice. If you are exploring clinical trials for advanced cancer, discuss the potential risks and requirements of Phase 3 enrollment with your physician.
Further reading
For more information on current treatment standards and research, visit our Cancer section.
